Title : COVID-19 Vaccines, What do we know so Far? A Narrative Review

Vol 4 No 5 (2021): Volume 04 Issue 05 May 2021

Article Date Published : 26 May 2021 | Page No.: 438-444 | Google Scholar | Crossref doi for this article

Abstract :

For more than a year, the world was paralyzed by the COVID-19 pandemic. It wasn’t until the last few months that hope to a return of a quasi-normal way of living was starting to materialize. The era of the COVID-19 vaccines begun, and with it all sorts of concerns and complaints about their safety and efficacy. Large numbers of people believed the conspiracy theories about the new vaccines thus becoming reluctant and sometimes refused to take the new vaccines. Others justified their concern with the relatively short trial periods compared to previous vaccines that used to take years before adoption.

Multiple vaccines emerged around the same time, and thus the fight to conquer the market began. Pfizer-BioNTech, Vaxzervria, Moderna, Sputnik, Coronavac, Janssen, all were rapidly distributed to countries around the globe, in order to reduce the mortality rate and control the pandemic. To make things worse, new viral mutations started being detected and thus shed more doubt on the efficacy of these vaccines.

This review article summarizes the literature of these vaccines’ pathophysiology, mechanism of action, dosing and schedule, safety profile and lastly the documented side effects of each vaccine.

In conclusion, there is no certainty whether these vaccines will prevent infection and more importantly protect against forward transmission. It is sure that the immunity persists for several months, but the exact duration for every vaccine is yet to be determined. For the time being, safety precautions must still be continued; wearing masks, social distancing and avoiding crowded places must be applied.

Keywords :

AstraZeneca, Coronavac, COVID-19, Johnson&Johnson, Moderna, Pfizer, Sputnik

References :

  1. Coronavirus disease 2019 (COVID-19) – Symptoms and causes. Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/coronavirus/symptoms-causes/syc-20479963 (accessed 29 April 2021).
  2. A Guide to Global COVID-19 Vaccine Efforts. Council on Foreign Relations, https://www.cfr.org/backgrounder/guide-global-covid-19-vaccine-efforts (accessed 29 April 2021).
  1. Vaccines and immunization: What is vaccination? https://www.who.int/news-room/q-a-detail/vaccines-and-immunization-what-is-vaccination (accessed 29 April 2021).
  2. Muhsen K, Abed El-Hai R, Amit-Aharon A, et al. Risk factors of underutilization of childhood immunizations in ultraorthodox Jewish communities in Israel despite high access to health care services. Vaccine 2012; 30: 2109–2115.
  3. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011; 12: 509–517.
  4. Corum, J., & Zimmer, C. (n.d.). How the Sinovac Vaccine Works. The New York Times. Retrieved April 23, 2021, from https://www.nytimes.com/interactive/2020/health/sinovac-covid-19-vaccine.html
  5. How the Sinovac Vaccine Works| Life Blog. (n.d.). BNI Life Insurance. Retrieved April 23, 2021, from https://www.bni-life.co.id/en/lifeblog/how-the-sinovac-vaccine-works
  6. What are nucleic acid vaccines and how could they be used against COVID-19? (n.d.). Retrieved April 21, 2021, from https://www.gavi.org/vaccineswork/what-are-nucleic-acid-vaccines-and-how-could-they-be-used-against-covid-19
  7. Organization, W. H. (2021). Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: Background document to the WHO interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing, 14 January 2021 (WHO/2019-nCoV/vaccines/SAGE_recommendation /BNT162b2/background/2021.1). Article WHO/2019-nCoV/vaccines/SAGE_recommendation/BNT162b2/ background/ 2021.1. https://apps.who.int/iris/handle/10665/338671
  8. Corum, J., & Zimmer, C. (n.d.). How the Johnson & Johnson Vaccine Works. The New York Times. Retrieved April 22, 2021, from https://www.nytimes.com/interactive/2020/health/johnson-johnson-covid-19-vaccine.html
  9. Sputnik V Vaccine. (n.d.). Retrieved April 22, 2021, from https://www.precisionvaccinations.com/vaccines/sputnik-v-vaccine
  10. Corum, J., & Zimmer, C. (n.d.). How the Oxford-AstraZeneca Vaccine Works. The New York Times. Retrieved April 22, 2021, from https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html
  11. What are viral vector-based vaccines and how could they be used against COVID-19? (n.d.). Retrieved April 22, 2021, from https://www.gavi.org/vaccineswork/what-are-viral-vector-based-vaccines-and-how-could-they-be-used-against-covid-19
  12. Different COVID-19 Vaccines. Centers for Disease Control and Prevention, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html (2021, accessed 29 April 2021).
  1. AstraZeneca vaccine: 3-month dosage interval might be preferable, https://www.medicalnewstoday.com/articles/astrazeneca-vaccine-3-month-dosage-interval-might-be-preferable (2021, accessed 29 April 2021).
  1. says ASKA. Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals. News-Medical.net, https://www.news-medical.net/news/20210329/Single-Sputnik-V-vaccine-dose-elicits-robust-immune-response-in-previously-infected-individuals.aspx (2021, accessed 29 April 2021).
  2. Writer S. Sputnik vaccine: Gap between 2 doses recommended at 21 days. Age, other details. mint, https://www.livemint.com/news/india/sputnik-vaccine-gap-between-two-doses-recommended-at-21-days-age-and-other-guidelines-here-11618296800401.html (2021, accessed 29 April 2021).
  1. CoronaVac COVID-19 Vaccine, https://www.precisionvaccinations.com/vaccines/coronavac-covid-19-vaccine (accessed 29 April 2021).
  2. Comparing the COVID-19 Vaccines: How Are They Different? Yale Medicine, https://www.yalemedicine.org/news/covid-19-vaccine-comparison (accessed 29 April 2021).
  1. Covid-19 roundup: Pfizer’s coronavirus vaccine seems highly effective against P.1 variant, study finds, https://www.advisory.com/Daily-Briefing/2021/03/12/coronavirus-roundup (accessed 29 April 2021).
  1. 9 S, 2021, Pm 6:10. Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil. Science | AAAS,https://www.sciencemag.org/news/2021/04/chinese-covid-19-vaccine-maintains-protection-variant-plagued-brazil (2021, accessed 29 April 2021).
  2. Sinovac: Brazil results show Chinese vaccine 50.4% effective. BBC News, 13 January 2021,  https://www.bbc.com/news/world-latin-america-55642648 (13 January 2021, accessed 29 April 2021).
  1. China’s Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection – Chile govt report. Reuters, https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-sinovac-covid-19-vaccine-67-effective-preventing-symptomatic-infection-2021-04-16/ (2021, accessed 29 April 2021).
  2. Benassatto L. Sinovac vaccine works on UK, South African variants – Brazil institute. Reuters, 17 February 2021, https://www.reuters.com/article/us-health-coronavirus-brazil-idUSKBN2AH2H0 (17 February 2021, accessed 29 April 2021).
  3. Cordell J. Russia’s Sputnik V Vaccine Less Effective Against South African Variant – U.S. Study. The Moscow Times, https://www.themoscowtimes.com/2021/04/06/russias-sputnik-v-vaccine-less-effective-against-south-african-variant-us-study-a73484 (2021, accessed 29 April 2021).
  4. Moderna vaccines promising vs variants in mouse study; no higher risk for poor outcomes found with UK variant. Reuters, https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-vaccines-promising-vs-variants-mouse-study-no-higher-risk-poor-outcomes-2021-04-14/ (2021, accessed 29 April 2021).
  5. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet 2021; 397: 671–681.
  6. Welle (www.dw.com) D. Fact check: How effective is the Sputnik V coronavirus vaccine? | DW | 15.04.2021. COM, https://www.dw.com/en/is-sputnik-v-vaccine-safe/a-57219314 (accessed 29 April 2021).
  7. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases 2021; 21: 181–192.
  8. Information about the Moderna COVID-19 Vaccine. Centers for Disease Control and Prevention, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html (2021, accessed 29 April 2021).
  9. Pfizer vs. Moderna Vaccines: Side Effects, Efficacy and More. NBC Chicago, https://www.nbcchicago.com/news/local/pfizer-vs-moderna-vaccines-side-effects-efficacy-and-more/2490162/ (accessed 29 April 2021).
  1. Fox JL. New Rotavirus Vaccines Appear Safe, Effective. Microbe Magazine 2006; 1: 110–111.
  2. Information about the Pfizer-BioNTech COVID-19 Vaccine. Centers for Disease Control and Prevention, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html (2021, accessed 29 April 2021).
  3. Vogel G, KupferschmidtMar. 23 K, 2021, et al. Data concerns and safety worries fuel crisis of confidence in AstraZeneca vaccine. Science | AAAS, https://www.sciencemag.org/news/2021/03/data-concerns-and-safety-worries-fuel-crisis-confidence-astrazeneca-vaccine (2021, accessed 29 April 2021).
  4. Morris S. Johnson & Johnson Janssen COVID-19 Vaccine Pause | Johns Hopkins Medicine, https://www.hopkinsmedicine.org/coronavirus/covid-19-vaccine/jj-vaccine-pause.html (accessed 29 April 2021).
  1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020; 383: 2603–2615.
  2. Safety update on COVID-19 vaccine Comirnaty finds no new concerns. Reactions Weekly 2021; 1842: 3–3.
  3. COVID-19 Vaccination. Centers for Disease Control and Prevention, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html (2020, accessed 29 April 2021).
  4. Understanding How COVID-19 Vaccines Work. Centers for Disease Control and Prevention, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html (2021, accessed 29 April 2021).
  1. Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC, https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html (2021, accessed 29 April 2021).
  2. Marnie C. COVID-19 vaccines: contraindications and precautionary advice. ANMJ, https://anmj.org.au/covid-19-vaccines-contraindications-and-precautionary-advice/ (2021, accessed 29 April 2021).

How to Cite :

COVID-19 Vaccines, What do we know so Far? A Narrative Review. Cima Hamieh, MD; Mahmoud El Hussein, MD; Yara Skaff, MD; Jim Abi Frem, MD; Elie Zaghrini, MD , 4(5), 438-444. Retrieved from https://ijcsrr.org/single-view/?id=3819&pid=3725

Most read articles by the same author(s)

Cima Hamieh, MD, Mahmoud El Hussein, MD, Yara Skaff, MD, Jim Abi Frem, MD, Elie Zaghrini, MD,

View

270

Citation

Downloads

Article Details